Hepatocellular Carcinoma
Conditions
Interventions
Intervention group:Transcatheter arterial embolization with a mixture of lipiodol and ethanol for PVTT
Intervention group:traditional TACE for intrahepatic portion
Control group:Traditional TACE
Sponsors
West China Hospital, Sichuan University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: (1) Unresectable HCC with PVTT (Vp3/Vp4); (2) No history of any disease-specific treatment including surgery in the past six months; (3) Optimal coagulation and liver function (Child-Pugh class A/B); (4) Eastern Cooperative Oncology Group (ECOG) score =2; (5) Informed consent of patient is available; (6) No serious concurrent medical illness; (7) Histologically or cytologically proved HCC except for lesions >2 cm, with typical features with one dynamic imaging technique and a-fetoprotein level > 40 ng/mL; (8) Tumor size up to 18 cm in the largest dimension; (9) Patients refused to receive sorafenib as the treatment for advanced HCC; (10) Patients allergic to ethanol should be included in the TACE group; (11) Patients had unsuccessful treated by sorafenib.
Exclusion criteria
Exclusion criteria: (1) Patients 75 years and older or less than 18 years; (2) Pregnant females with HCC; (3) History of variceal bleeding within the past 3 months; (4) Patients with active hepatitis B (HBV-DNA> 1000 copies/ml); (5) History of acute tumor rupture with hemoperitoneum; (6) Concurrent ischemic heart disease or heart failure; (7) History of hepatic encephalopathy; (8) Thrombosis of target hepatic artery.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| overall survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| adverse event;effective response; | — |
Countries
China
Contacts
Public ContactZhengyin Liao
West China Hospital, Sichuan University
Outcome results
None listed